Lansoprazole
/ / Lansoprazole, Lansoprazole, Prevacid (lansoprazole) is a small molecule pharmaceutical. Lansoprazole was first approved as Prevacid on 1995-05-10. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, helicobacter infections, and stomach ulcer amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Lansoprazole, Prevacid (discontinued: Lansoprazole, Prevacid)
CombinationsLansoprazole, amoxicillin clarithromycin (discontinued: Lansoprazole, amoxicillin clarithromycin, Prevacid naprapac, Prevpac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lansoprazole
Lansoprazole
+
Naproxen
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| basic care lansoprazole | ANDA | 2022-12-13 |
| berkley and jensen lansoprazole | ANDA | 2020-06-01 |
| careone acid reducer | ANDA | 2022-11-15 |
| caring mill lansoprazole | ANDA | 2021-09-02 |
| dg health lansoprazole | ANDA | 2024-02-08 |
| equaline lansoprazole | ANDA | 2023-06-21 |
| equate lansoprazole | New Drug Application | 2022-12-07 |
| equate lansoprazole delayed release | ANDA | 2020-05-06 |
| foster and thrive acid reducer | ANDA | 2023-09-14 |
| good neighbor pharmacy lansoprazole | ANDA | 2022-08-08 |
Show 19 more
Indications
FDA
EMA
Show 29 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lansoprazole, Lansoprazole, Dexcel | |||
| 11077055 | 2036-04-21 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC03: Lansoprazole
— A02BC53: Lansoprazole, combinations
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD02: Lansoprazole, tetracycline and metronidazole
— A02BD03: Lansoprazole, amoxicillin and metronidazole
— A02BD07: Lansoprazole, amoxicillin and clarithromycin
— A02BD09: Lansoprazole, clarithromycin and tinidazole
— A02BD10: Lansoprazole, amoxicillin and levofloxacin
HCPCS
No data
Clinical
Clinical Trials
300 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 14 | 11 | 13 | 23 | 21 | 78 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 11 | 19 | 7 | 39 |
| Esophagitis | D004941 | HP_0100633 | K20 | 3 | 8 | 15 | 8 | 1 | 34 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 6 | 6 | 12 | 6 | 5 | 34 |
| Healthy volunteers/patients | — | — | — | 26 | — | 1 | 4 | — | 31 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 18 | 6 | 5 | 29 |
| Helicobacter infections | D016481 | EFO_1000961 | — | — | 1 | 4 | 13 | 6 | 23 |
| Stomach ulcer | D013276 | — | K25 | — | — | 11 | 2 | 1 | 14 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | 5 | 7 | 2 | 14 |
| Heartburn | D006356 | — | R12 | 3 | 3 | 5 | 4 | — | 14 |
Show 65 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | — | 10 | — | 3 | 13 |
| Recurrence | D012008 | — | — | — | 2 | 1 | — | 2 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | 1 | — | 1 | 3 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 2 | — | 1 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 2 | 1 | — | — | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 3 |
| Covid-19 | D000086382 | — | — | — | — | 2 | — | 1 | 3 |
| Gout | D006073 | EFO_0004274 | M10 | — | 1 | 1 | — | — | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | — | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 2 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | 1 | — | — | — | 1 |
| Avulsion fractures | D000071562 | — | — | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Homeostasis | D006706 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 2 | 2 |
| Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 2 | 2 |
| Non-erosive reflux disease | D000096663 | — | — | — | — | — | — | 2 | 2 |
| Aortic valve disease | D000082862 | — | — | — | — | — | — | 1 | 1 |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | — | — | — | 1 | 1 |
| Tricuspid valve insufficiency | D014262 | HP_0005180 | — | — | — | — | — | 1 | 1 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 1 | 1 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lansoprazole |
| INN | lansoprazole |
| Description | Lansoprazole is a member of benzimidazoles, a member of pyridines and a sulfoxide. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 103577-45-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL480 |
| ChEBI ID | 6375 |
| PubChem CID | 3883 |
| DrugBank | DB00448 |
| UNII ID | 0K5C5T2QPG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Lansoprazole
+
Amoxicillin
+
Clarithromycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lansoprazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Lansoprazole
+
Naproxen
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,409 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72,019 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use